Cover Image
Market Research Report

Europe Rat Model Market Forecast 2019-2027

Published by Inkwood Research Product code 513978
Published Content info 72 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Rat Model Market Forecast 2019-2027
Published: January 20, 2019 Content info: 72 Pages
Description

KEY FINDINGS

The Europe rat model market is expected to grow from $XX thousand in 2018 to $XX thousand by the year 2027 at an anticipated CAGR of 7.67% for the forecast year 2019-2027. Improving genome editing techniques, rapid increase and ease in availability of results in transgenic rats and a growing interest of biotech and pharma companies in the market are the major drivers for the boom in the rat model market.

MARKET INSIGHTS

Germany has the largest market share in the European market owing to a large number of fiscal investments in research areas and profitable research related schemes. The market is broadly segmented into three categories: by type, by component and by the application. By type, the outbred rat type is expected to dominate the global rat model market with expected growth at a CAGR of XX%. By components, the services sector currently holds the largest market share, although the technology segment is anticipated to grow faster at a CAGR of xx% during the forecast period. But, the rules and regulations on the animal testing permit that allows the practice of non-human organisms for scientific research do fluctuate greatly throughout the world. This is expected to hamper the growth of the said market in future.

COMPETITIVE INSIGHTS

Research scientists and top pharmaceutical companies are increasingly using rat models for medical as well as clinical research. The top companies using these models are Oncodesign S.A., Vivo Biotech Ltd., Janvier Labs, Transviragen Inc., Genoway S.A., Charles River Laboratories Inc., Sage Labs Inc. (Acquired By Horizon Discovery Group PLC), Taconic Biosciences, Envigo, Clea Japan, Laboratory Corporation of America Holdings, Cyagen Biosciences Inc., Hera Biolabs Inc., Biomere and Transposagen Biopharmaceuticals Inc.

Table of Contents
Product Code: 15906

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. OUTBRED RAT TYPE HOLDS THE MAJOR SHARE IN THE RAT MODEL MARKET
    • 3.2.2. ONCOLOGY IS THE FASTEST GROWING APPLICATION
    • 3.2.3. RAT CARE PRODUCTS ARE SIGNIFICANTLY GROWING

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. ENHANCEMENT IN GENOME EDITING
    • 4.2.2. GROWING AVAILABILITY OF TRANSGENIC RAT
    • 4.2.3. SWELLING PHARMACEUTICAL AND BIOTECHNOLOGY CORPORATIONS R&D
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
    • 4.3.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
    • 4.3.3. USE OF ZEBRAFISH IN RESEARCH IS THE GROWING MODEL
    • 4.3.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
    • 4.4.2. ESCALATION IN MONOCLONAL ANTIBODY CREATION
  • 4.5. MARKET CHALLENGES
    • 4.5.1. HIGHLY EXPENSIVE RAT MODEL

5. MARKET BY RAT TYPE

  • 5.1. INBRED
  • 5.2. GENETICALLY ENGINEERED RATS
  • 5.3. SURGICALLY MODIFIED RATS
  • 5.4. HYBRID
  • 5.5. OUTBRED
  • 5.6. IMMUNE-DEFICIENT

6. MARKET BY APPLICATION

  • 6.1. DIABETES
  • 6.2. TOXICOLOGY
  • 6.3. ONCOLOGY
  • 6.4. IMMUNOLOGY & INFLAMMATION
  • 6.5. OTHER APPLICATION

7. MARKET BY COMPONENT

  • 7.1. TECHNOLOGY
    • 7.1.1. NUCLEAR TRANSFERASE
    • 7.1.2. MICROINJECTION
    • 7.1.3. EMBRYONIC STEM CELL INJECTION
    • 7.1.4. OTHER TECHNOLOGY
  • 7.2. SERVICES
  • 7.3. RAT CARE PRODUCTS
    • 7.3.1. FEED
    • 7.3.2. BEDDING
    • 7.3.3. CAGES
    • 7.3.4. OTHER RAT CARE PRODUCTS

8. KEY ANALYTICS

  • 8.1. PORTER'S FIVE FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE PRODUCT
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIERS
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. VALUE CHAIN ANALYSIS
  • 8.3. REGULATORY FRAMEWORK
  • 8.4. KEY BUYING CRITERIA
    • 8.4.1. HIGH ACCURACY
    • 8.4.2. HIGH EFFICACY
    • 8.4.3. QUALITY OF OPERATING PROCEDURE
    • 8.4.4. PRICE
  • 8.5. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. EUROPE
    • 9.1.1. THE UNITED KINGDOM
    • 9.1.2. FRANCE
    • 9.1.3. GERMANY
    • 9.1.4. SPAIN
    • 9.1.5. ITALY
    • 9.1.6. REST OF EUROPE

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET POSITION ANALYSIS
  • 10.2. COMPANY PROFILES
    • 10.2.1. BIOMERE
      • 10.2.1.1. COMPANY OVERVIEW
      • 10.2.1.2. PRODUCT PORTFOLIO
      • 10.2.1.3. SCOT ANALYSIS
    • 10.2.2. CHARLES RIVER LABORATORIES INC.
      • 10.2.2.1. COMPANY OVERVIEW
      • 10.2.2.2. PRODUCT PORTFOLIO
      • 10.2.2.3. SCOT ANALYSIS
      • 10.2.2.4. STRATEGIC INITIATIVES
    • 10.2.3. CLEA JAPAN
      • 10.2.3.1. COMPANY OVERVIEW
      • 10.2.3.2. PRODUCT PORTFOLIO
      • 10.2.3.3. SCOT ANALYSIS
      • 10.2.3.4. STRATEGIC INITIATIVES
    • 10.2.4. CYAGEN BIOSCIENCES INC.
      • 10.2.4.1. COMPANY OVERVIEW
      • 10.2.4.2. PRODUCT PORTFOLIO
      • 10.2.4.3. SCOT ANALYSIS
    • 10.2.5. ENVIGO
      • 10.2.5.1. COMPANY OVERVIEW
      • 10.2.5.2. PRODUCT PORTFOLIO
      • 10.2.5.3. STRATEGIC INITIATIVES
    • 10.2.6. GENOWAY S.A.
      • 10.2.6.1. COMPANY OVERVIEW
      • 10.2.6.2. PRODUCT PORTFOLIO
      • 10.2.6.3. SCOT ANALYSIS
      • 10.2.6.4. STRATEGIC INITIATIVES
    • 10.2.7. HERA BIOLABS INC.
      • 10.2.7.1. COMPANY OVERVIEW
      • 10.2.7.2. PRODUCT PORTFOLIO
      • 10.2.7.3. SCOT ANALYSIS
      • 10.2.7.4. STRATEGIC INITIATIVE
    • 10.2.8. JANVIER LABS
      • 10.2.8.1. COMPANY OVERVIEW
      • 10.2.8.2. PRODUCT PORTFOLIO
      • 10.2.8.3. SCOT ANALYSIS
    • 10.2.9. LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 10.2.9.1. COMPANY OVERVIEW
      • 10.2.9.2. PRODUCT PORTFOLIO
      • 10.2.9.3. STRATEGIC INITIATIVES
    • 10.2.10. ONCODESIGN S.A.
      • 10.2.10.1. COMPANY OVERVIEW
      • 10.2.10.2. PRODUCT PORTFOLIO
      • 10.2.10.3. SCOT ANALYSIS
      • 10.2.10.4. STRATEGIC INITIATIVE
    • 10.2.11. SAGE LABS INC. (ACQUIRED BY HORIZON DISCOVERY GROUP PLC)
      • 10.2.11.1. COMPANY OVERVIEW
      • 10.2.11.2. PRODUCT PORTFOLIO
      • 10.2.11.3. SCOT ANALYSIS
      • 10.2.11.4. STRATEGIC INITIATIVES
    • 10.2.12. TACONIC BIOSCIENCES
      • 10.2.12.1. COMPANY OVERVIEW
      • 10.2.12.2. PRODUCT PORTFOLIO
      • 10.2.12.3. SCOT ANALYSIS
      • 10.2.12.4. STRATEGIC INITIATIVES
    • 10.2.13. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
      • 10.2.13.1. COMPANY OVERVIEW
      • 10.2.13.2. PRODUCT PORTFOLIO
      • 10.2.13.3. SCOT ANALYSIS
      • 10.2.13.4. STRATEGIC INITIATIVES
    • 10.2.14. TRANSVIRAGEN INC.
      • 10.2.14.1. COMPANY OVERVIEW
      • 10.2.14.2. PRODUCT PORTFOLIO
      • 10.2.14.3. SCOT ANALYSIS
    • 10.2.15. VIVO BIOTECH LTD.
      • 10.2.15.1. COMPANY OVERVIEW
      • 10.2.15.2. PRODUCT PORTFOLIO
      • 10.2.15.3. SCOT ANALYSIS
      • 10.2.15.4. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1 EUROPE RAT MODEL MARKET 2019-2027 ($ MILLION)
  • TABLE 2 BENEFITS OF RAT TRANSGENIC
  • TABLE 3 EUROPE RAT MODEL MARKET BY RAT TYPE 2019-2027 ($ MILLION)
  • TABLE 4 EXAMPLES OF INBRED RATS AND RESEARCH APPLICATIONS
  • TABLE 5 EUROPE INBRED MARKET 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE GENETICALLY ENGINEERED RATS MARKET 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE SURGICALLY MODIFIED RATS MARKET 2019-2027 ($ MILLION)
  • TABLE 8 EUROPE HYBRID MARKET 2019-2027 ($ MILLION)
  • TABLE 9 EUROPE OUTBRED MARKET 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE IMMUNE-DEFICIENT MARKET 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE RAT MODEL MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE DIABETES MARKET 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE TOXICOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 14 EUROPE ONCOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 15 EUROPE IMMUNOLOGY & INFLAMMATION MARKET 2019-2027 ($ MILLION)
  • TABLE 16 EUROPE OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
  • TABLE 17 EUROPE RAT MODEL MARKET BY COMPONENT 2019-2027 ($ MILLION)
  • TABLE 18 EUROPE TECHNOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 19 EUROPE NUCLEAR TRANSFERASE MARKET 2019-2027 ($ MILLION)
  • TABLE 20 EUROPE MICRO INJECTION MARKET 2019-2027 ($ MILLION)
  • TABLE 21 EUROPE EMBRYONIC STEM CELL INJECTION MARKET 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE OTHER TECHNOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 23 EUROPE SERVICES MARKET 2019-2027 ($ MILLION)
  • TABLE 24 EUROPE RAT CARE PRODUCTS MARKET 2019-2027 ($ MILLION)
  • TABLE 25 EUROPE FEED MARKET 2019-2027 ($ MILLION)
  • TABLE 26 POPULAR FOOD FOR RATS
  • TABLE 27 EUROPE BEDDING MARKET 2019-2027 ($ MILLION)
  • TABLE 28 EUROPE CAGES MARKET 2019-2027 ($ MILLION)
  • TABLE 29 EUROPE OTHER RAT CARE PRODUCTS MARKET 2019-2027 ($ MILLION)
  • TABLE 30 EUROPE RAT MODEL MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 31 RAT MODEL COMPANY POSITION ANALYSIS

LIST OF FIGURES

  • FIGURE 1 EUROPE RAT MODEL MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 EUROPE RAT MODEL MARKET SHARE BY RAT TYPE 2018 & 2027 (%)
  • FIGURE 3 EUROPE RAT MODEL MARKET BY INBRED 2019-2027 ($ MILLION)
  • FIGURE 4 EUROPE RAT MODEL MARKET BY GENETICALLY ENGINEERED RATS 2019-2027 ($ MILLION)
  • FIGURE 5 EUROPE RAT MODEL MARKET BY SURGICALLY MODIFIED RATS 2019-2027 ($ MILLION)
  • FIGURE 6 EUROPE RAT MODEL MARKET BY HYBRID 2019-2027 ($ MILLION)
  • FIGURE 7 EUROPE RAT MODEL MARKET BY OUTBRED 2019-2027 ($ MILLION)
  • FIGURE 8 EUROPE RAT MODEL MARKET BY IMMUNE-DEFICIENT 2019-2027 ($ MILLION)
  • FIGURE 9 EUROPE RAT MODEL MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 10 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
  • FIGURE 11 EUROPE RAT MODEL MARKET BY DIABETES 2019-2027 ($ MILLION)
  • FIGURE 12 EUROPE RAT MODEL MARKET BY TOXICOLOGY 2019-2027 ($ MILLION)
  • FIGURE 13 EUROPE RAT MODEL MARKET BY ONCOLOGY 2019-2027 ($ MILLION)
  • FIGURE 14 EUROPE RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2019-2027 ($ MILLION)
  • FIGURE 15 EUROPE RAT MODEL MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)
  • FIGURE 16 EUROPE RAT MODEL MARKET SHARE BY COMPONENT 2018 & 2027 (%)
  • FIGURE 17 EUROPE RAT MODEL MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
  • FIGURE 18 EUROPE RAT MODEL MARKET BY NUCLEAR TRANSFERASE 2019-2027 ($ MILLION)
  • FIGURE 19 EUROPE RAT MODEL MARKET BY MICRO INJECTION 2019-2027 ($ MILLION)
  • FIGURE 20 EUROPE RAT MODEL MARKET BY EMBRYONIC STEM CELL INJECTION 2019-2027 ($ MILLION)
  • FIGURE 21 EUROPE RAT MODEL MARKET BY OTHER TECHNOLOGY 2019-2027 ($ MILLION)
  • FIGURE 22 EUROPE RAT MODEL MARKET BY SERVICES 2019-2027 ($ MILLION)
  • FIGURE 23 EUROPE RAT MODEL MARKET BY RAT CARE PRODUCTS 2019-2027 ($ MILLION)
  • FIGURE 24 EUROPE RAT MODEL MARKET BY FEED 2019-2027 ($ MILLION)
  • FIGURE 25 EUROPE RAT MODEL MARKET BY BEDDING 2019-2027 ($ MILLION)
  • FIGURE 26 EUROPE RAT MODEL MARKET BY CAGES 2019-2027 ($ MILLION)
  • FIGURE 27 EUROPE RAT MODEL MARKET BY OTHER RAT CARE PRODUCTS 2019-2027 ($ MILLION)
  • FIGURE 28 PORTER'S FIVE FORCE MODEL
  • FIGURE 29 THE UNITED KINGDOM RAT MODEL MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 FRANCE RAT MODEL MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 GERMANY RAT MODEL MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 SPAIN RAT MODEL MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 ITALY RAT MODEL MARKET 2019-2027 ($ MILLION)
  • FIGURE 34 REST OF EUROPE RAT MODEL MARKET 2019-2027 ($ MILLION)
Back to Top